Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer Announces Five-Year Partnership with the World Federation of Hemophilia Humanitarian Aid Program

Bayer announced a five-year partnership with the World Federation of Hemophilia Humanitarian Aid Program, which will bring education, training and Bayer’s full portfolio of recombinant Factor VIII treatments to healthcare professionals in more than 60 countries where access to care is limited.

Read More »

Synlogic Announces Clinical Collaboration with Roche

Synlogic Inc. announced a new clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine SYNB1891 – a dual innate immune activator engineered to express a STING agonist – in combination with Roche’s PD-L1-blocking checkpoint inhibitor atezolizumab (marketed as Tecentriq) in patients with advanced solid tumors.

Read More »

Dana-Farber Scientists Win Checkpoint Inhibitor Patent Lawsuit

Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.

Read More »

Entyvio Superior to Humira in Ulcerative Colitis

Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.

Read More »

FDA approves first anticoagulant for pediatric patients to treat potentially life-threatening blood clots

The U.S. FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism in pediatric patients 1 month of age and older.

Read More »

Pfizer’s abrocitinib meets late-stage study goals

Pfizer Inc.’s experimental atopic dermatitis treatment abrocitinib met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease.

Read More »

FDA Approves Bavencio Plus Inlyta Combination for Patients with Advanced Renal Cell Carcinoma

EMD Serono and Pfizer announced that the U.S. FDA approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma.

Read More »

FDA Approves Eylea for Diabetic Retinopathy

The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.

Read More »

Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial

Mallinckrodt plc announced that the company achieved target enrollment of 300 participants in the Phase 3 CONFIRM clinical study to evaluate the efficacy and safety of the investigational agent terlipressin in adult patients with Hepatorenal Syndrome Type 1 (HRS-1).

Read More »

Moderna Reports Influenza Vaccine Study Results

Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom